Phase 1b trial of enfortumab vedotin in combination with checkpoint inhibitors in patients with metastatic urothelial cancer.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Enfortumab vedotin (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- 01 Aug 2017 Status changed from not stated to planning.
- 01 Aug 2017 New trial record
- 27 Jul 2017 According to a Seattle Genetics media release, this trial expected to start late in 2017.